DNA synthesis disruption

DNA synthesis disruption refers to any process, pathological event, or pharmacological intervention that impairs or halts the replication of DNA in cells. Many widely used anticancer and antiviral drugs act by disrupting DNA synthesis either directly (inhibiting replicative enzymes like DNA polymerases or causing DNA lesions that stall replication forks) or indirectly (depleting nucleotide pools or inhibiting accessory enzymes such as topoisomerases). While disrupting DNA synthesis is an effective strategy for killing rapidly dividing cancer or infected cells, it also affects normal proliferating tissues, leading to notable toxicity. Additionally, DNA synthesis disruption is linked to genome instability and plays a role in carcinogenesis and various genetic disorders when it occurs due to endogenous damage or inherited defects in replication machinery. This target entry should be replaced with specific enzymes or proteins within the DNA replication machinery (e.g., "DNA polymerase alpha", "DNA topoisomerase II"), not the generic process descriptor "DNA synthesis disruption".

Direct inhibition of DNA polymerase (e.g., by nucleoside analogs); DNA damage causing replication stalling or block (e.g., alkylators, crosslinkers); Depletion of nucleotide pools, indirectly inhibiting synthesis (antimetabolites); Inhibition of replication fork enzymes (e.g., topoisomerase inhibitors, helicase inhibitors).